---
layout: default
title: Activated Charcoal Antimony Trisulfide Arsenic Tri
parent: 僅模型預測 (L5)
nav_order: 186
evidence_level: L5
indication_count: 0
---

# Activated Charcoal Antimony Trisulfide Arsenic Tri
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Component Mixture (Activated Charcoal / Arsenic Trioxide / Nux-Vomica et al.): Insufficient Data for Repurposing Evaluation

## One-Sentence Summary

This submission contains a 12-component mixture (including activated charcoal, arsenic trioxide, cinchona bark, podophyllum root, and strychnos nux-vomica seed) whose identity suggests a homeopathic or traditional compound preparation.
The TxGNN model returned **no predicted indications** for this combination, as the mixture could not be mapped to a single DrugBank entity.
With **0 clinical trials**, **0 publications**, and **0 regulatory approvals** on record, there is insufficient evidence to assess repurposing potential at this stage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | None on record |
| Predicted New Indication | None (TxGNN returned no prediction) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction only; in this case even model output is absent |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN prediction is available for this submission. The primary reason is that the query drug is a 12-ingredient mixture with no associated DrugBank ID, preventing the knowledge graph from resolving it as a single pharmacological entity. TxGNN operates on individual molecules or well-characterized compounds; multi-component mixtures — especially those combining botanical extracts, heavy metal salts, and mineral agents — fall outside its standard mapping scope.

Several individual components do have documented pharmacological activity. Arsenic trioxide (ATO) is an approved antineoplastic agent used in acute promyelocytic leukemia. Podophyllum peltatum root is the natural source of podophyllotoxin, a precursor to etoposide and teniposide. Cinchona bark provides quinine alkaloids with antimalarial and antiarrhythmic history. Silver nitrate carries antimicrobial properties. Strychnos nux-vomica seed contains strychnine, a potent CNS stimulant with a very narrow therapeutic index. The combination of these agents does not correspond to any recognized modern pharmaceutical formulation.

Until each active ingredient is individually profiled and a primary therapeutic hypothesis is defined, meaningful repurposing analysis cannot proceed.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## US Market Information

No US regulatory authorizations on record for this combination product.

---

## Cytotoxicity

At least two components of this mixture carry known cytotoxic activity:

| Item | Content |
|------|---------|
| Cytotoxicity Classification | Mixed — contains conventional cytotoxic agents (arsenic trioxide; podophyllum-derived alkaloids) alongside non-cytotoxic components |
| Myelosuppression Risk | Indeterminate for the mixture; arsenic trioxide alone carries a risk of QT prolongation and myelosuppression at therapeutic doses |
| Emetogenicity Classification | Indeterminate; arsenic trioxide monotherapy is classified low-to-moderate emetogenic |
| Monitoring Items | If arsenic trioxide is present at therapeutic concentrations: ECG (QTc), CBC, liver and renal function, electrolytes (K⁺, Mg²⁺) |
| Handling Protection | Arsenic trioxide and podophyllum derivatives require cytotoxic drug handling precautions; the mixture as a whole should be treated accordingly until further characterization |

---

## Safety Considerations

Please refer to the package insert for safety information. Given the presence of arsenic trioxide (cardiac toxicity, APL differentiation syndrome) and strychnos nux-vomica seed (strychnine — convulsive, narrow therapeutic window), this mixture carries significant toxicity risk from individual components and should not proceed to any evaluation without formal toxicological profiling.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline cannot generate a repurposing prediction for an unresolved multi-component mixture with no DrugBank ID, no original indication, and no existing evidence base; all three preconditions for a meaningful evaluation are absent.

**To proceed, the following is needed:**

- **Clarify product identity**: Determine whether this is a registered homeopathic product, a traditional compound formula, or a data entry error. Provide the brand name and country of registration if available.
- **Decompose into individual INNs**: Submit each active ingredient separately (e.g., arsenic trioxide, podophyllotoxin) to TxGNN for individual repurposing scoring.
- **Obtain DrugBank IDs** for each component with available pharmacological data.
- **Toxicological risk assessment**: Several components (arsenic trioxide, strychnine, silver nitrate, antimony trisulfide) carry significant human toxicity; a safety threshold analysis must precede any repurposing consideration.
- **Define primary therapeutic hypothesis**: If a specific component (e.g., arsenic trioxide) is the intended active agent, isolate that compound and re-submit as a single-drug evidence pack.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

